Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

Lyell Immunopharma announced positive results from a phase 1/2 trial of LYL314, a CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. Among patients treated in the third- or ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

JNJ-4496, formerly known as C-CAR039, is a dual-targeting CAR T designed to bind to both CD19 and CD20 antigens — two cell surface proteins commonly expressed on malignant B-cells. This design ...

People are beginning to realize that dogs share a lot more with humans than just their homes and habits. Some spontaneously occurring cancers in dogs are genetically very similar to those in people ...

In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea ...

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell ...

The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...

Federal budget cuts have created "a climate of anxiety" among medical researchers, says Maximilian F. Konig, a rheumatologist ...

If I’d gone flat after my mastectomy, I might be healthy now, but my breast implants led to more cancer, heart failure and years of pain.